Related Experiment Video
Updated: Sep 9, 2025
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies
1Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.
Abstract:
TP53 mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming. The tumor microenvironment in TP53-mutated MDS and AML fosters leukemic progression through cytokine dysregulation, altered metabolism, and immune suppression. Current therapies, including chemotherapy and hypomethylating agents, offer limited efficacy, resulting in poor overall survival rates for these high-risk patients. However, novel therapeutic approaches provide promising avenues, including MDM2 inhibitors, p53-reactivating agents, pathway-targeted inhibitors (Hedgehog, Wnt, NF-κB), immune modulation (checkpoint inhibitors, CAR-T therapy), metabolic interventions (fatty acid metabolism, glycolysis), and gene-editing technologies (CRISPR/Cas9, base editing). This review explores the mechanisms of immune dysfunction in TP53-mutated MDS and AML while highlighting emerging therapeutic strategies, emphasizing the integration of targeted, metabolic, and immune-modulating therapies as a transformative approach to improve patient outcomes.
Insights
TP53 mutations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) lead to immune evasion and treatment resistance. Emerging therapies targeting these mutations, metabolism, and immune pathways offer new hope for high-risk patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- TP53 mutations are key drivers of oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- These mutations impair critical p53-regulated functions, including apoptosis, immune surveillance, and genomic stability, promoting immune evasion and metabolic reprogramming.
- The tumor microenvironment in TP53-mutated MDS and AML exacerbates leukemic progression via cytokine dysregulation, metabolic alterations, and immune suppression.
Purpose of the Study:
- To review the mechanisms of immune dysfunction in TP53-mutated MDS and AML.
- To highlight emerging therapeutic strategies for these challenging hematologic malignancies.
- To emphasize the potential of integrated therapies for improving patient outcomes.
Main Methods:
- Literature review of mechanisms underlying TP53 mutations in MDS and AML.
- Analysis of current therapeutic limitations and emerging treatment modalities.
- Exploration of novel therapeutic targets including molecular pathways, metabolism, and immune modulation.
Main Results:
- TP53 mutations disrupt normal cellular functions, leading to immune evasion and altered tumor microenvironment.
- Current therapies show limited efficacy in TP53-mutated MDS and AML, correlating with poor survival rates.
- A range of novel therapies, including MDM2 inhibitors, p53-reactivating agents, pathway-specific inhibitors, immune modulators, metabolic interventions, and gene editing, show promise.
Conclusions:
- Integrated therapeutic approaches combining targeted agents, metabolic interventions, and immune modulation represent a promising strategy for TP53-mutated MDS and AML.
- Addressing the complex interplay between TP53 mutations, the tumor microenvironment, and immune dysfunction is crucial for therapeutic success.
- Further research and clinical trials are needed to validate these novel strategies and improve outcomes for patients with high-risk MDS and AML.
Related Concept Videos
02:17The Tumor Microenvironment
02:23Abnormal Proliferation